Table 1: The incidence of adverse events reported in more than 5% of participants and the doses at which they occurred [8].
| Adverse Effect | Placebo n = 75 | Balovaptan 1.5 mg n = 32 | Balovaptan 4 mg n = 77 | Balovaptan 10 mg n = 39 |
| Headache | 21.3% | 12.5% | 13% | 12.8% |
| Anxiety | 8% | 6.3% | 0 | 10.3% |
| Fatigue | 6.7% | 6.3% | 1.3% | 10.3% |
| Abdominal discomfort | 2.7% | 0 | 2.6% | 10.3% |
| Upper airway infection | 5.3% | 3.1% | 9.1% | 5.1% |
| Weight gain | 2.7% | 12.5% | 5.2% | 0 |
| Nasopharyngitis | 4% | 9.4% | 5.2% | 0 |
| Irritability | 5.3% | 3.1% | 9.1% | 5.1% |